8-K: Adial Pharmaceuticals Announces Positive Results from AD04 Pharmacokinetics Study, Paving Way for Phase 3 Trial

Adial Pharmaceuticals has completed a pharmacokinetics study of AD04, showing positive results including dose-proportional exposure and no food effect, which is a key step towards their Phase 3 trial for Alcohol Use Disorder.

Summary

• Adial Pharmaceuticals has successfully completed a pharmacokinetics (PK) study for their drug candidate AD04, intended for the treatment of Alcohol Use Disorder (AUD).
• The study involved 30 healthy adult volunteers and evaluated the bioavailability and dose proportionality of AD04.
• Results showed that AD04 0.33mg delivered lower ondansetron exposure than a 4mg reference standard, but exposure increased proportionally with dose across a 3-fold range.
• The study also confirmed that AD04 can be taken with or without food, which is a positive finding for patient convenience.
• This study fulfills an FDA requirement and provides crucial data for optimizing the design of the upcoming Phase 3 clinical trial for AD04.
• The company plans to engage with the FDA in Q4 2024 to discuss the study results and finalize the Phase 3 trial program.

Sentiment

Score: 8

Explanation: The document presents positive results from a key study, which is a significant step towards Phase 3 trials. The language is optimistic and forward-looking, indicating a positive outlook for the company's drug development program.

Positives

• The study confirmed dose-proportional increases in ondansetron exposure with AD04.
• AD04 can be taken in fed or fasted states, which simplifies administration.
• The study completion satisfies an FDA requirement for the Phase 3 trial.
• The study results will help optimize the Phase 3 trial design.
• The study supports a 505(b)(2) regulatory pathway application with the FDA.
• The study was completed in a relatively short time and at a low cost.

Negatives

• The 0.33mg dose of AD04 delivered lower ondansetron exposure than the 4mg reference standard, which was expected due to the lower dose.

Risks

• The success of the Phase 3 trial is not guaranteed, and the company will need to obtain regulatory approvals.
• The company's ability to maintain partnerships and secure funding for research and development is crucial.
• There are risks associated with the acceptance of AD04 in the marketplace and the successful commercialization of the product.
• The company's ability to maintain its Nasdaq listing is also a risk.

Future Outlook

Adial plans to use the data from this study to optimize the design of their Phase 3 clinical trial for AD04 and engage with the FDA in Q4 2024 to discuss the results and finalize the trial program. They also intend to pursue a 505(b)(2) regulatory pathway for approval.

Management Comments

• Cary Claiborne, President and CEO, stated that the study achieves the goal of obtaining data needed to design a more precise and informed Phase 3 trial protocol.
• Claiborne also noted that the study's completion is in accord with previous FDA guidance and is intended to enhance the likelihood of success in the upcoming Phase 3 trial.
• He highlighted that the study was a key element of their strategy to advance ongoing partnership discussions.

Industry Context

This announcement is significant in the context of the biopharmaceutical industry's focus on developing targeted therapies for addiction. The positive results from the pharmacokinetics study of AD04 position Adial as a potential player in the AUD treatment market, which currently has limited effective options.

Comparison to Industry Standards

• The use of a 505(b)(2) regulatory pathway is a common strategy for drug development, allowing companies to leverage existing data to expedite the approval process, similar to companies like Alkermes and Indivior who have used this pathway for addiction treatments.
• The study design, including the use of a crossover study with healthy volunteers, is a standard approach in pharmacokinetics research, comparable to studies conducted by other pharmaceutical companies developing new drug formulations.
• The focus on genetic markers to identify patients who are more likely to respond to AD04 is a trend in personalized medicine, similar to the approach taken by companies like Myriad Genetics in other therapeutic areas.

Stakeholder Impact

• Shareholders will likely view the positive study results as a positive development for the company's future prospects.
• The successful development of AD04 could provide a new treatment option for patients with Alcohol Use Disorder.
• The company's employees may be positively impacted by the progress of the drug development program.

Next Steps

• Adial will use the study data to optimize the design of the Phase 3 clinical trial for AD04.
• The company plans to engage with the FDA in Q4 2024 to discuss the study results and finalize the Phase 3 trial program.
• Adial will continue to advance ongoing partnership discussions.
• The company will prepare an application for approval of AD04 under a 505(b)(2) regulatory pathway with the FDA.

Key Dates

Keywords

AD04, Alcohol Use Disorder, Pharmacokinetics, Phase 3 Trial, Ondansetron, FDA, Bioavailability, Serotonin-3 receptor antagonist, Genetically targeted therapy, Addiction